Accordingly, Hu et al. demonstrated the presence of ARCH-associated TP53 variants at MAF ranging from 0.3 to 1.9% upon NGS of DNA extracted from the plasma of 5/33 NSCLC patients (47). Here, TP53 is linked to non-small cell lung carcinoma.